Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial

Journal:

The Lancet Oncology

Published:

2025-10-30

DOI:

10.1016/s1470-2045(25)00472-3

Affiliations:

30

Authors:

34

Go to article

Institutions	Authors	Share
Servier Pharmaceuticals LLC., United States of America (USA)	6.000000	0.18
University of California, Los Angeles (UCLA), United States of America (USA)	2.000000	0.06
University of Michigan (U-M), United States of America (USA)	1.000000	0.03
Sylvester Comprehensive Cancer Center (Sylvester), UM, United States of America (USA)	1.000000	0.03
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.03
Sunnybrook Health Sciences Centre, U of T, Canada	1.000000	0.03
Kyoto University, Japan	1.000000	0.03
Bottomley Consulting Group, Belgium	1.000000	0.03
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.03
University Hospital of Lausanne (CHUV), UNIL, Switzerland	1.000000	0.03
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA)	1.000000	0.03
Erasmus University Medical Center (Erasmus MC), Netherlands	1.000000	0.03
Hospital Universitario 12 de Octubre, Spain	1.000000	0.03
Ohio State University Wexner Medical Center (OSUWMC), United States of America (USA)	1.000000	0.03
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)	1.000000	0.03
AP-HP Pitié-Salpêtrière Hospital, France	1.000000	0.03
University of Turin (UNITO), Italy	1.000000	0.03
Cancer Research Center of Lyon (CRCL), France	1.000000	0.03
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.03
The Royal Marsden Hospital (Surrey), United Kingdom (UK)	1.000000	0.03
Rabin Medical Center (RMC), TAU, Israel	1.000000	0.03
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	1.000000	0.03
University of California, San Francisco (UCSF), United States of America (USA)	1.000000	0.03
Tel Aviv Sourasky Medical Center, Israel	1.000000	0.03
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.03
Duke University Health System, United States of America (USA)	1.000000	0.03
German Cancer Research Center in the Helmholtz Association (DKFZ), Germany	0.500000	0.02
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany	0.500000	0.02

Interested in Oncology and Carcinogenesis?